Table 1.
Characteristics of included trials on Qianggu Capsule for POP
| Study ID | Sample size (EG/CG) | Diagnostic criteria | Age (yrs, mean) Sex (male/female) | Course of disease | Experimental group | Comparison group | Duration of treatment | Outcome assessment |
|---|---|---|---|---|---|---|---|---|
| Gu and Guo 2004 [38] | 82 (41/41) | Chinese criteria | EG: 63.2 (26/15) CG: 62.7 (29/12) |
NR | QC (0.25 g, Tid) | Calcium gluconate (3 pills, Tid) | 3 months | BMD (LS) ADR |
| Zhao et al. 2004 [39] | 69 (34/35) | NR | EG: NR CG: NR |
NR | QC (0.25 g, Tid) | Livial (1.25 mg, Qd) | 6 months | BMD (LS、FN) ADR |
| Xia and Chen 2006 [40] | 58 (29/29) | Chinese criteria | EG: 58.6 ± 6.3 (0/29) CG: 57.9 ± 6.7 (0/29) |
NR | QC (0.25 g, Tid) + CG | Caltrate D (600 mg, Qd) | 12 months | BMD (LS、FN、WA、FGT) ADR |
| Ji 2006 [41] | 62 (40/22) | Chinese criteria | EG: 65.3 (12/28) CG: 65.2 (6/16) |
EG: 3.6 years CG: 3.5 years |
QC (0.25 g, Tid) | Vitamin D2 and calcium hydrogen phosphate tablets (0.15 g, Tid) | 3 months | BMD (ulna、radius) |
| Shan and Zhou 2006 [42] | 62 (32/30) | Chinese criteria | EG: 60.32 ± 4.58 (13/19) CG: 60.96 ± 5.06 (12/18) |
NR | QC (0.25 g, Tid) | α-D3 capsule (0.5 μg, Bid) | 3 months | BMD (LS、FN、FT) Ca、P、ALP ADR |
| Wang et al. 2007 [43] | 54 (28/26) | NR | EG: 61.8 ± 6.1 (0/28) CG: 62.3 ± 5.9 (0/26) |
NR | QC (0.25 g, Tid) | α-D3 capsule (0.5 μg, Bid) | 6 months | BMD (LS、FN) Ca、P、ALP、 NTX/Cr ADR |
| Li and Zhao 2008 [44] | 60 (30/30) | Chinese criteria | EG: 61.8 ± 6.1 (0/30) CG: 62.3 ± 5.9 (0/30) |
NR | QC (0.25 g, Tid) + Calcium tablet (1 pill, qd) |
QC placebo + Calcium tablet (1 pill, qd) |
6 months | BMD (LS) BGP、CT、E2、PTH、HOP/Cr |
| Gao 2008 [45] | 128 (64/64) | Chinese criteria | EG: 66.23 ± 7.24 (24/40) CG: 65.14 ± 7.51 (26/38) |
NR | QC (0.25 g, Tid) | α-D3 capsule (0.5 ~ 1 μg, Bid) | 6 months | BMD (LS、FN、WA、FT) ADR |
| Xu et al. 2010 [46] | 80 (40/40) | Chinese criteria | EG: NR (0/40) CG: NR (0/40) |
NR | QC (0.25 g, Tid) + CG | Alendronate (70 mg, once a week) |
6 months | BMD (LS、WA) ADR |
| Zeng et al. 2013 [47] | 150 (75/75) | Chinese criteria | EG: 70.4 ± 5.8 (39/36) CG: 70.0 ± 5.2 (41/34) |
EG: 6.8 years CG: 6.7 years |
QC (0.25 g, Tid) + CG | Caltrate D (600 mg, Qd) | 12 months | BMD (LS、FN、FGT) |
NOTE: EG experimental group, CG comparison group, NR not reported, QC qianggu capsule, LS lumbar spine, FN femoral neck, WA wards area, FGT femoral great trochanter, FT femoral trochanteric, Ca calcium, P phosphorus, ALP alkaline phosphatase, BGP bone gla protein, CT calcitonin, E 2 estradiol, PTH parathyroid hormone, NTX urinary N-telopeptides of type I collagen, HOP urinary hydroxyproline, Cr Creatinine, ADR adverse drug reaction